For research use only. Not for therapeutic Use.
Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells[1].
Bivatuzumab (10 μg/mL) stains CD44v6 in STS cells[1].
| Catalog Number | I042426 |
| CAS Number | 214559-60-1 |
| Purity | ≥95% |
| Reference | [1]. Leuci V,et al. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology. 2018 Feb 15;7(5):e1423167. |
